Pilgrim Partners Asia Pte Ltd Buys New Position in Edwards Lifesciences Co. (NYSE:EW)

Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 880 shares of the medical research company’s stock, valued at approximately $65,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $26,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter worth about $30,000. Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $54,000. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on EW shares. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Citigroup upped their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $79.95.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares of the company’s stock, valued at $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares of the company’s stock, valued at $2,153,526.69. The trade was a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,553 shares of company stock worth $4,513,064. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $69.39 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The business’s 50-day moving average price is $71.74 and its two-hundred day moving average price is $70.62. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $40.79 billion, a P/E ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.